Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.59 |
| ▸ | AR | P10275 | 4/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599443 | 1.00 | CTSB (0.59) | CTSBARNOTUMTDP1KEAP1 | |
| SCHEMBL5240888 | 0.92 | CTSB (0.66) | CTSBARTDP1KMT2AALDH1A1 | |
| SCHEMBL2559524 | 0.84 | NOTUM (0.65) | NOTUMTDP1KMT2AALDH1A1LMNA | |
| SCHEMBL17599441 | 0.79 | NOTUM (0.61) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL17612866 | 0.79 | NOTUM (0.61) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL24811432 | 0.79 | NOTUM (0.61) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL4879663 | 0.78 | CTSB (0.74) | CTSBARTDP1KMT2AALDH1A1 | |
| SCHEMBL2558464 | 0.78 | NOTUM (0.56) | NOTUMTDP1KMT2AALDH1A1 | |
| SCHEMBL2553837 | 0.78 | NOTUM (0.56) | NOTUMTDP1KMT2AALDH1A1LMNA | |
| SCHEMBL2559422 | 0.77 | ALDH1A1 (0.69) | CTSBNOTUMTDP1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997966-A1 | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |